Race Oncology Ltd
ASX:RAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Race Oncology Ltd
ASX:RAC
|
AU |
|
Palo Alto Networks Inc
BMV:PANW
|
US |
|
Indo Kordsa Tbk PT
IDX:BRAM
|
ID |
|
Meltwater NV
OSE:MWTR
|
NL |
|
Hologic Inc
NASDAQ:HOLX
|
US |
|
S
|
Seegene Inc
KOSDAQ:096530
|
KR |
|
Rexford Industrial Realty Inc
NYSE:REXR
|
US |
|
C
|
Cameco Corp
NYSE:CCJ
|
CA |
Race Oncology Ltd
Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.
Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.
